Global Melanoma Drug Forecast and Market Analysis to 2029 – Featuring Amgen, Bayer and Bristol Myers Squibb Among Others – ResearchAndMarkets.com

Global Melanoma Drug Forecast and Market Analysis to 2029 – Featuring Amgen, Bayer and Bristol Myers Squibb Among Others – ResearchAndMarkets.com




Global Melanoma Drug Forecast and Market Analysis to 2029 – Featuring Amgen, Bayer and Bristol Myers Squibb Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Melanoma – Global Drug Forecast and Market Analysis to 2029” report has been added to ResearchAndMarkets.com’s offering.

Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic melanoma is treated with systemic therapy with either PD-1 monotherapy (Opdivo or Keytruda) or BMS’ combination therapy of Opdivo + CTLA-4 inhibitor Yervoy. BRAF V600-positive patients also have the option of receiving targeted therapy.

The global market is expected to grow from $5.6B in 2019 to $7.46B in 2029 at a CAGR of 2.9%. The introduction of 12 new pipeline agents as well as label expansions of currently approved agents are key drivers of this market growth. However, multiple patent expiries of market-leading brands, occurring across the 8MM, will prohibit growth.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 12 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM are key patent expiries of immune checkpoint inhibitors and targeted BRAF/MEK inhibitors
  • Among the late-stage pipeline products and marketed agents, immune checkpoint inhibitors are expected to generate the greatest revenues over the forecast period.
  • The most important unmet needs in the melanoma market include: wider therapeutic options for patients who progress on immune checkpoint inhibitors, effective treatment for patients with brain metastases, biomarkers to guide treatment decisions, and wider options for patients with acquired resistance to targeted therapy.

Key Questions Answered

  • 12 late-stage pipeline agents are expected to enter the melanoma market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs melanoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

  • Overview of melanoma including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline melanoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting melanoma therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).
  • Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to –

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global melanoma therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned

  • Amgen
  • Bayer
  • Bristol Myers Squibb
  • Checkmate Pharmaceuticals
  • Chipscreen Biosciences
  • Clinigen
  • Eisai
  • Genentech/Roche
  • HUYA Biosciences
  • Idera Pharmaceuticals
  • Iovance Biotherapeutics
  • Merck & Co.
  • Nektar Therapeutics
  • Novartis
  • OncoSec Medical
  • Pfizer/Array BioPharma
  • Philogen S.p.A
  • Polynoma LLC
  • Ultimovacs ASA

For more information about this report visit https://www.researchandmarkets.com/r/p23joj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900